The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been...

Descripción completa

Detalles Bibliográficos
Autores principales: Suda, Goki, Nakai, Masato, Sho, Takuya, Kimura, Megumi, Shimazaki, Tomoe, Maehara, Osamu, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Baba, Masaru, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478991/
https://www.ncbi.nlm.nih.gov/pubmed/30568153
http://dx.doi.org/10.2169/internalmedicine.2077-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478991/
https://www.ncbi.nlm.nih.gov/pubmed/30568153
http://dx.doi.org/10.2169/internalmedicine.2077-18

Ejemplares similares